Best Ccus Podcasts (2024)

1
Episode 5 | Policy Before Pipes: Fast-Tracking a Regulatory Framework for CCUS 38:26

16d ago38:26

38:26

"The fifth instalment of the ‘FSR Policy Briefcase’ explores the why, when, and how of carbon capture utilisation and storage (CCUS) in Europe. For this episode, regular hosts Leonardo Meeus and James Kneebone are joined by part-time Professor of FSR Christopher Jones. The conversation builds on the recent publication of Christopher's Policy Brief …

1
Ep 6 | Carbon pricing trends in the EU and China with Yan Qin 20:58

7d ago20:58

20:58

In this episode we spoke to Yan Qin, Lead Carbon Analyst at the London Stock Exchange Group LSEG. We discuss recent trends and drivers of EU carbon prices, interactions between gas and carbon prices and price trends in the Chinese national ETS. The interview was led by Marie Raude and Lea Heinrich, Research Associates at the Climate Team of the Flo…

1
How the nuclear market can be restructured and reimagined to effectively tackle industrial decarbonisation and the energy transition 41:03

7d ago41:03

41:03

In this episode we look to a very specific nuclear technology that reuses nuclear waste. You’ll hear from Andrew Murdoch, the Managing Director of UK Ops for newcleo as he talks through the structural and market changes that would support wider use of nuclear as a clean energy. Key takeaways to listen out for: What it takes to create a zero carbon …

1
Live From Bonn (SB60): CCS, the UNFCCC Process and International Policy Developments 24:48

8d ago24:48

24:48

Serving as a mid-way point ahead of COP, and as one of the most crucial climate convenings, the Bonn Climate Change Conference brings together the UNFCCC’s permanent subsidiary bodies, inclusive of both the Subsidiary Body for Scientific and Technological Advice (SBSTA) and the Subsidiary Body for Implementation (SBI). Working in tandem to address …

1
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks 46:31

9d ago46:31

46:31

While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that remains is the treatment of patients following the failure of erythropoiesis-stimulating agents (ESAs). In this podcast, experts Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Valeria Santini, MD, Univers…

1
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients 34:39

17d ago34:39

34:39

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial …

1
Securing authentic customer-driven demand for the energy transition and its critical projects 41:35

17d ago41:35

41:35

Krista Johnson brings a real passion for enabling universal access to clean energy to this episode of the podcast. Listen in for a conversation that explores what it means to get true customer-driven demand for projects and how to engage authentically and positively with the neighbours and stakeholders of your projects. Anyone working to execute ma…

1
Shaping the CCS Resurgence in Canada 27:36

1M ago27:36

27:36

Canada is no stranger to carbon capture and storage, having launched CCS projects in Alberta and Saskatchewan. As the country looks to scale-up the technology to support its climate targets, tackling policy and regulatory roadblocks, picking up on lessons learned and rolling out financial incentives will be a key focus.Listen in as we speak with Be…

1
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies 12:34

1M ago12:34

12:34

Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immu…

1
Rebuilding global fertiliser market infrastructure to drive net zero 26:31

1M ago26:31

26:31

Join Alex Cameron for this episode which welcomes Petter Østbø, former CEO of EuroChem and Founder/CEO of AtlasAgro. You’ll hear about the route to net zero in global fertilisers and the development of AtlasAgro’s ‘plant of the future’. The economic realities that large fertilizer companies face, largely due to fossil fuel-based assets and the natu…

1
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials 27:24

1M ago27:24

27:24

The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field. In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, …

1
The Future of Cement 26:59

2M ago26:59

26:59

In this episode of the Clinker Factor, Ian Riley talks to Matthias Mersmann, CTO of KHD Humboldt Wedag, and WCA Member, about the latest developments in cement technology and how the industry is addressing the challenges of climate change.By World Cement Association

1
Episode 4 | Invisible but detectable! Regulating and pricing methane emissions in Europe and at sea 39:56

2M ago39:56

39:56

The fourth instalment of the ‘FSR Policy Briefcase’ explores the subject of methane emissions, specifically the establishment of a Methane Regulation in the EU, as well as the increasing attention methane is receiving in the maritime sector, both maritime fuel emissions and leakages from LNG shipments. For this episode, regular hosts Leonardo Meeus…

1
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs 11:43

2M ago11:43

11:43

Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients. Today's VJHemOnc podcast features experts Mary Frances McM…

1
Guest Podcast: The price of everything - SAF 40:57

2M ago40:57

40:57

This week we are partnering with General Index to share their episode which explores the market and pricing dynamics around SAF. We chose this episode as our Guest Podcast because of the links with co2 reuse, industrial decarbonization as well as the opportunity to host a discussion which was more focused on the economics of a key green product. Th…

1
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome 22:50

2M ago22:50

22:50

Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week's VJHemOnc podcast, we'll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD. Tune in as experts Moham…

1
Bruno Fux, Siam City Cement: Driving decarbonisation and sustainability at Siam City Cement 39:24

2M ago39:24

39:24

In this week’s podcast, Bruno Fux joins Alex Cameron to discuss the challenges and opportunities that lie ahead for decarbonisation in Vietnam, and specifically his plans for Siam City Cement. considering the country's commitment to net zero emissions by 2050. You’ll hear a comparison of Siam City Cement's initiatives vs those in regions benefiting…

1
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs 43:51

2M ago43:51

43:51

In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting the value of collaboration between specialists when treating patients with hematological malignancies. Furthermore, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines aim to help he…

1
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification 22:22

3M ago22:22

22:22

Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field. In this week's podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, …

1
Steve Meller, Founder & CEO, CH4 Global: Reducing methane in cattle with the twin focus of radical climate impact plus a profitable, marketable and scalable tech platform 54:24

3M ago54:24

54:24

Steve Meller, Founder and CEO of CH4 Global, joined Alex to talk about the scale up of his company which is focused on massively reducing methane emissions from cattle using a seaweed technology. Steve Meller brings experience from the corporate, entrepreneurial and academic world to his leadership of CH4 Global – all are playing their part from th…

1
Episode 3 | How can clean hydrogen contribute to European industrial decarbonisation? 50:17

3M ago50:17

50:17

The third instalment of the ‘FSR Policy Briefcase’ explores European industrial policy following the energy crisis of 2021/22, specifically the role of clean hydrogen in the protection and continuation of existing energy-intensive industrial sectors as well as in generating new, clean industrial growth. For this episode, regular hosts Leonardo Meeu…

1
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors 13:02

3M ago13:02

13:02

Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies, indicating early stages of blood disorders that may progress to more serious conditions such as leukemia or myelodysplastic syndromes (MDS). In this podcast, Uma Borate, MD, The Oh…

1
Developments in CCUS and SCMs 28:39

3M ago28:39

28:39

In the latest episode of the Clinker Factor, Ian Riley talks to Fouad Kammoun, Director Sales – Near East, Middle East and Central Asia of Thyssenkrupp Industrial Solutions AG, about his experience in the cement industry and the organisation's latest projects in developing carbon capture technology.By World Cement Association

1
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception 9:39

3M ago9:39

9:39

Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the blood. MBL is considered a precursor condition to chronic lymphocytic leukemia (CLL); however, not all cases of MBL progress to CLL, and many individuals with MBL do not require treatment. In this podcast, Stephen Ansel…

1
Is Seratech’s CCU Technology a Practical Way of Using a Cement Plant’s Emissions? 17:56

3M ago17:56

17:56

In this episode of the Clinker Factor, Ian Riley talks to Sam Draper, CEO of Seratech, about Seratech’s technology, business model and whether the technology can be scaled to a size interesting to a cement plant.By World Cement Association

1
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT 13:00

3M ago13:00

13:00

The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies explor…

1
Characterizing the opportunity and unique challenges for India’s clean energy transition: Jai Asundi of CSTEP 53:43

3M ago53:43

53:43

India’s watershed moment in climate-terms was the Paris COP where commitments were made on co2 sequestration, co2 intensity and renewables. More recently at COP Last year more commitments were made including hitting Net Zero by 2070. India is a developing industrial nation that needs to balance the right of a population to seek better overall livin…

1
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology 33:31

4M ago33:31

33:31

While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due to the highly varied presentation of this disease. As clinicians and researchers work to improve outcomes for patients, there is increasing importance being placed on the role of the multidisciplinary team in treating the…

1
Episode 2 | Was the energy crisis the key to completing EU electricity market integration? 31:16

4M ago31:16

31:16

The second instalment of the ‘FSR Policy Briefcase’ with Ellen Beckstedde and Emma Menegatti is a detailed discussion on the energy crisis of 2021/2022. Regular hosts Leonardo Meeus and James Kneebone are joined by electricity market experts Ellen Beckstedde and Emma Menegatti, both Research Associates at the Florence School of Regulation. The conv…

1
Ep 5 | The U.S. Inflation Reduction Act and European carbon pricing with Sanjay Patnaik 10:37

4M ago10:37

10:37

In this episode we speak to Sanjay Patnaik, Director of the Center on Regulation and Markets (CRM), Bernard L. Schwartz Chair in Economic Policy Development, and Senior Fellow in Economic Studies at Brookings. We discuss the impact of the U.S. Inflation Reduction Act, opportunities for joint climate action between the U.S. and the EU, and the impac…

1
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy 13:02

4M ago13:02

13:02

Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding the use of these agents. One ongoing challenge is the prevention and management of CAR-T-related toxicities, including immune effector cell-associated hematotoxicity (ICAHT), as well as how to im…

1
What industrials need to know about co2 transport and storage with Malc Kent, CGG 56:25

4M ago56:25

56:25

CCS drives discussion whether you’re for it, against it or just hope it’s a solution you’ll be able to use. In this episode, Alex Cameron talks with Malc Kent to get to the heart of the questions that industrial members of the Decarbonization Leaders Network ask, specifically: o What do we really know about the safety and security of long term unde…

1
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks 12:58

4M ago12:58

12:58

The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today's episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discu…

1
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents 12:10

4M ago12:10

12:10

The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT3 inhibitors, IDH inhibitors, and menin inhibitors. Menin inhibitors are currently being explored in several clinical trials, both as monotherapy and in combination with other agents. In this podcast, …

1
Innovation On Product And Business Model 25:00

4M ago25:00

25:00

In our first podcast of 2024, Ian Riley talks to Thomas Atkinson, Head of International Affairs at Hoffmann Green Cement, about the award winning clinker free technology developed by Hoffmann and their approach to promoting their products directly with developers.By World Cement Association

1
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023 18:16

5M ago18:16

18:16

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS; HR-MDS). Treatment and management strategies vary for LR-MDS versus HR-MDS, and a number of challenges remain in the field. In this podcast, you will hear from leading experts who discuss several t…

1
Driving CCS Projects In Emerging Economies – Insights From Brazil 37:56

5M ago37:56

37:56

Emerging economies are turning to CCS to tackle emissions from industry and Brazil is no exception. Home to one of the largest CCS projects in the world, the country is now looking to drive CCS investment by developing supportive regulatory frameworks. Listen in as we speak to Nathalia Weber, co-founder and director of CCS Brasil, on how the countr…

1
Episode 1 | Energy policy ideas for the next European Commission 32:29

5M ago32:29

32:29

The first installment of the ‘FSR Policy Briefcase’ features the recent flagship Policy Brief ‘Energy policy ideas for the next European Commission: from targets to investments’ written by some of the most senior researchers at the Florence School of Regulation. Lead author and FSR Director Leonardo Meeus joined Research Associate James Kneebone fo…

1
Turning £66m seed money into £200m+ of co investment (and growing): The Transforming Foundation Industries Challenge 47:23

5M ago47:23

47:23

This episode steps back to the early innovation cycle that is still needed to accelerate industrial decarbonisation. Bruce Adderley joins the podcast to explore how the £66m of the TFI Challenge in the UK has had an amplified effect, securing £200m+ of co-investment for collaborations across steel, cement, chem, glass and more of the foundation ind…

1
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine 12:21

5M ago12:21

12:21

In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several agents being evaluated in clinical trials, the future looks promising for patients. Despite these advances, there are challenges and unmet needs which remain, and both clinicians and researchers are working to addre…

1
Updates, challenges and novel agents being explored in BPDCN 9:49

5M ago9:49

9:49

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain in the diagnosis, treatment and management of this disease, with a lack of clinical trials in the field. However, clinicians and researchers are working to improve upon these unmet needs, …

1
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets 18:18

5M ago18:18

18:18

The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options, with associated benefits and challenges. Several ongoing clinical trials in the field are investigating potential treatment approaches and addressing many unanswered questions. In this podcast, Moham…

1
Point Source Carbon Capture: Amines, MOFs, Membranes – Understanding the pro’s and con’s with Erica Nemser of CMS 37:01

5M ago37:01

37:01

If you’re an industrial or an investor exploring the Carbon Capture space, listen in to this conversation with Erica Nemser, CEO of Compact Membrane System, and Alex Cameron, CEO of Decarb Connect. You’ll hear about the growing ecosystem, types of point source carbon capture technology – and also will get the inside story on how CMS is scaling its …

1
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy 11:04

5M ago11:04

11:04

In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recently approved gene therapies. There are several ongoing trials evaluating the safety of these agents in patients, with promising results being demonstrated. In this podcast, leading experts Rabi Hanna, M…

1
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis 10:29

6M ago10:29

10:29

In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis and risk stratification remain a challenge, clinicians and researchers are working to improve upon these. Furthermore, novel immunotherapies are being explored in the field, providing hope for patients…

1
Abby Smith, Team Pennsylvania: The essential role of a neutral convener in driving forward state-wide decarbonization opportunities 39:09

6M ago39:09

39:09

Team Pennsylvania (Team PA) has 27 years of history as a non-partisan organisation convening public-private partnerships are critical economic opportunities. Abby Smith joins Alex to talk about what the role of neutral convener can do to accelerate non-partisan pathways around decarbonization (and other issues) and just what it is that they do to b…

1
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF 17:12

6M ago17:12

17:12

The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed in recent years. Several clinical trials are exploring the safety and efficacy of novel agents and combinations, with promising advances being made. At the 65th ASH Annu…

1
National Highways – how a major buyer can work with industry and contractors to build a market for low carbon strategic materials 42:59

6M ago42:59

42:59

National Highways owns the strategy for a significant proportion of the UK’s roads and are a major buyer of asphalt, cement and steel. In this podcast you’ll join Alex Cameron, Founder of Decarb Connect, in conversation with the Executive Director of Procurement, Malcolm Dare, and the Director of Environmental Sustainability, Steve Elderkin, to lea…

1
CCS Progress at COP 28 19:45

6M ago19:45

19:45

Every year, the UN’s Conference of the Parties (COP) sees thousands of delegates and attendees from around the world – including the Global CCS Institute – make their way to the international climate summit to address global warming and move the needle on climate solutions. This year, there was ample carbon capture and storage (CCS) discussions at …

1
iwNHL 2023 Session V: Expanding the CAR platform in NHL 10:59

6M ago10:59

10:59

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

Podcasts Worth a Listen

Ccus Podcasts

Podcasts Worth a Listen

Quick Reference Guide